Loading...
XNAS
SNOA
Market cap2mUSD
Jul 09, Last price  
1.26USD
1D
1.61%
1Q
-44.74%
Jan 2017
-99.86%
IPO
-100.00%
Name

Sonoma Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:SNOA chart
P/E
P/S
0.11
EPS
Div Yield, %
Shrs. gr., 5y
53.19%
Rev. gr., 5y
0.95%
Revenues
20m
+36.68%
4,543,0003,835,0005,388,0007,364,0009,754,00012,744,00015,452,00013,668,00013,854,0009,369,00012,825,00016,658,00018,970,00017,928,00018,629,00012,628,00013,272,00012,735,00014,288,00019,529,000
Net income
-3m
L-8.16%
-19,783,000-20,339,000-17,656,000-8,232,000-7,948,000-7,329,000-5,431,0003,735,000-8,203,000-10,162,0009,274,000-14,328,000-11,798,000-3,308,000-3,950,000-5,086,000-5,151,000-4,835,000-3,457,000-3,175,000
CFO
-4m
L+4,369.32%
-18,082,000-17,446,000-16,832,000-6,639,000-4,429,000-4,032,0001,150,000-4,890,000-6,694,000-8,746,000-8,167,000-12,439,000-11,717,000-4,591,000-3,378,000-4,248,000-6,152,000-2,398,000-88,000-3,933,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
IPO date
Jan 26, 2007
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT